{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:30:16Z","timestamp":1791873016965,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02287-w","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:58:43Z","timestamp":1790053123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated baseline C-reactive protein is associated with treatment failure and shorter survival after Yttrium-90 radioembolization in hepatocellular carcinoma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0646-7839","authenticated-orcid":false,"given":"Enes Mustafa","family":"Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-1600","authenticated-orcid":false,"given":"Burcu","family":"Esen Akka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-169X","authenticated-orcid":false,"given":"Tevfik","family":"G\u00fczelbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2869-6842","authenticated-orcid":false,"given":"\u00c7a\u011fr\u0131","family":"Erdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-5817","authenticated-orcid":false,"given":"Mustafa Fatih","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-6407","authenticated-orcid":false,"given":"Cihan","family":"\u015ein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-7762","authenticated-orcid":false,"given":"Halil Burak","family":"Kapucu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5006-7136","authenticated-orcid":false,"given":"Ay\u015fe Bet\u00fcl","family":"Dere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-8173","authenticated-orcid":false,"given":"Meryem","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2287_CR1","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","volume":"31","author":"F Safri","year":"2024","unstructured":"Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024;31:1105\u201312. https:\/\/doi.org\/10.1038\/s41417-024-00764-w.","journal-title":"Cancer Gene Ther"},{"key":"2287_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"2287_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/MNM.0000000000001991","volume":"46","author":"BE Akkas","year":"2025","unstructured":"Akkas BE, Sin C, Akgun E, Guzelbey T, Erdim C, Vural Topuz O, et al. Tumoricidal dosing approach with parenchymal sparing using voxel-based dosimetry in 90 Y glass microspheres treatment of hepatocellular carcinoma. Nucl Med Commun. 2025;46:692\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001991.","journal-title":"Nucl Med Commun"},{"key":"2287_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000541539","volume":"14","author":"K Chen","year":"2025","unstructured":"Chen K, Tong AKT, Moe FNN, Ng DCE, Lo RHG, Gogna A, et al. The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation. Liver Cancer. 2025;14:158\u201379. https:\/\/doi.org\/10.1159\/000541539.","journal-title":"Liver Cancer"},{"key":"2287_CR5","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49:3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2287_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. J Nucl Med. 2024;65:264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"2287_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"2287_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00270-017-1622-4","volume":"40","author":"M Seidensticker","year":"2017","unstructured":"Seidensticker M, Powerski M, Seidensticker R, Damm R, Mohnike K, Garlipp B, et al. Cytokines and (90)Y-Radioembolization: Relation to Liver Function and Overall Survival. Cardiovasc Intervent Radiol. 2017;40:1185\u201395. https:\/\/doi.org\/10.1007\/s00270-017-1622-4.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2287_CR9","doi-asserted-by":"publisher","unstructured":"Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res. 2020;6. https:\/\/doi.org\/10.20517\/2394-5079.2020.57.","DOI":"10.20517\/2394-5079.2020.57"},{"key":"2287_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-018-0048-z","volume":"2","author":"LX Yu","year":"2018","unstructured":"Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2:6. https:\/\/doi.org\/10.1038\/s41698-018-0048-z.","journal-title":"NPJ Precis Oncol"},{"key":"2287_CR11","doi-asserted-by":"publisher","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","volume":"10","author":"S Shrotriya","year":"2015","unstructured":"Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS ONE. 2015;10:e0143080. https:\/\/doi.org\/10.1371\/journal.pone.0143080.","journal-title":"PLoS ONE"},{"key":"2287_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1186\/s12885-023-11693-6","volume":"23","author":"KY Lin","year":"2023","unstructured":"Lin KY, Chen QJ, Tang SC, Lin ZW, Zhang JX, Zheng SM, et al. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients. BMC Cancer. 2023;23:1190. https:\/\/doi.org\/10.1186\/s12885-023-11693-6.","journal-title":"BMC Cancer"},{"key":"2287_CR13","doi-asserted-by":"publisher","first-page":"e0216677","DOI":"10.1371\/journal.pone.0216677","volume":"14","author":"T Meischl","year":"2019","unstructured":"Meischl T, Rasoul-Rockenschaub S, Gyori G, Sieghart W, Reiberger T, Trauner M, et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. PLoS ONE. 2019;14:e0216677. https:\/\/doi.org\/10.1371\/journal.pone.0216677.","journal-title":"PLoS ONE"},{"key":"2287_CR14","doi-asserted-by":"publisher","unstructured":"Muller L, Hahn F, Mahringer-Kunz A, Stoehr F, Gairing SJ, Michel M, et al. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13195018.","DOI":"10.3390\/cancers13195018"},{"key":"2287_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000449337","volume":"5","author":"H Nakanishi","year":"2016","unstructured":"Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, et al. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer. 2016;5:257\u201368. https:\/\/doi.org\/10.1159\/000449337.","journal-title":"Liver Cancer"},{"key":"2287_CR16","doi-asserted-by":"publisher","first-page":"e82225","DOI":"10.1371\/journal.pone.0082225","volume":"8","author":"Z Weng","year":"2013","unstructured":"Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, et al. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS ONE. 2013;8:e82225. https:\/\/doi.org\/10.1371\/journal.pone.0082225.","journal-title":"PLoS ONE"},{"key":"2287_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0044-1779715","volume":"41","author":"A Villalobos","year":"2024","unstructured":"Villalobos A, Pisanie JLD, Gandhi RT, Kokabi N. Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips. Semin Intervent Radiol. 2024;41:63\u201378. https:\/\/doi.org\/10.1055\/s-0044-1779715.","journal-title":"Semin Intervent Radiol"},{"key":"2287_CR18","unstructured":"NCI. Version 5.0 ed; Common Terminology Criteria for Adverse Events. National Institutes of Health website. Accessed 21 September 2025."},{"key":"2287_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/curroncol28010095","volume":"28","author":"Y Kim","year":"2021","unstructured":"Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, et al. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol. 2021;28:965\u201377. https:\/\/doi.org\/10.3390\/curroncol28010095.","journal-title":"Curr Oncol"},{"key":"2287_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.7150\/ijms.6050","volume":"10","author":"Z Zheng","year":"2013","unstructured":"Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013;10:653\u201364. https:\/\/doi.org\/10.7150\/ijms.6050.","journal-title":"Int J Med Sci"},{"key":"2287_CR21","doi-asserted-by":"publisher","first-page":"101539","DOI":"10.1016\/j.aohep.2024.101539","volume":"30","author":"MS Franze","year":"2025","unstructured":"Franze MS, Vigneron P, Sessa A, Saitta C, Chalaye J, Tacher V, et al. Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy. Ann Hepatol. 2025;30:101539. https:\/\/doi.org\/10.1016\/j.aohep.2024.101539.","journal-title":"Ann Hepatol"},{"key":"2287_CR22","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. PLoS ONE. 2023;18:e0294236. https:\/\/doi.org\/10.1371\/journal.pone.0294236.","journal-title":"PLoS ONE"},{"key":"2287_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-021-00791-w","volume":"11","author":"O Ocal","year":"2021","unstructured":"Ocal O, Kupcinskas J, Morkunas E, Amthauer H, Schutte K, Malfertheiner P, et al. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res. 2021;11:51. https:\/\/doi.org\/10.1186\/s13550-021-00791-w.","journal-title":"EJNMMI Res"},{"key":"2287_CR24","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1074\/jbc.271.16.9503","volume":"271","author":"D Zhang","year":"1996","unstructured":"Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996;271:9503\u20139. https:\/\/doi.org\/10.1074\/jbc.271.16.9503.","journal-title":"J Biol Chem"},{"key":"2287_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","volume":"146","author":"DN Ngwa","year":"2022","unstructured":"Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Mol Immunol. 2022;146:50\u20136. https:\/\/doi.org\/10.1016\/j.molimm.2022.04.003.","journal-title":"Mol Immunol"},{"key":"2287_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018;287:1050\u20138. https:\/\/doi.org\/10.1148\/radiol.2018171768.","journal-title":"Radiology"},{"key":"2287_CR27","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.hpb.2019.12.007","volume":"22","author":"N Bhutiani","year":"2020","unstructured":"Bhutiani N, O\u2019Brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, et al. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere). HPB (Oxford). 2020;22:1330\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2019.12.007.","journal-title":"HPB (Oxford)"},{"key":"2287_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","volume":"68","author":"C Spreafico","year":"2018","unstructured":"Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68:724\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2017.12.026.","journal-title":"J Hepatol"},{"key":"2287_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41598-024-84835-w","volume":"15","author":"C Yang","year":"2025","unstructured":"Yang C, Liang Z, Zhao L, Li R, Ma P. Prediction of microvascular invasion in hepatocellular carcinoma using a preoperative serum C-reactive protein-based nomogram. Sci Rep. 2025;15:522. https:\/\/doi.org\/10.1038\/s41598-024-84835-w.","journal-title":"Sci Rep"},{"key":"2287_CR30","doi-asserted-by":"publisher","first-page":"e231386","DOI":"10.1148\/radiol.231386","volume":"311","author":"A Sarwar","year":"2024","unstructured":"Sarwar A, Malik MS, Vo NH, Tsai LL, Tahir MM, Curry MP, et al. Efficacy and Safety of Radiation Segmentectomy with (90)Y Resin Microspheres for Hepatocellular Carcinoma. Radiology. 2024;311:e231386. https:\/\/doi.org\/10.1148\/radiol.231386.","journal-title":"Radiology"},{"key":"2287_CR31","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/cncr.20976","volume":"103","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856\u201364. https:\/\/doi.org\/10.1002\/cncr.20976.","journal-title":"Cancer"},{"key":"2287_CR32","doi-asserted-by":"publisher","first-page":"774823","DOI":"10.3389\/fonc.2021.774823","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li Z, Huang Z, Yu X, Zheng L, Xu J. C-Reactive Protein Is an Indicator of the Immunosuppressive Microenvironment Fostered by Myeloid Cells in Hepatocellular Carcinoma. Front Oncol. 2021;11:774823. https:\/\/doi.org\/10.3389\/fonc.2021.774823.","journal-title":"Front Oncol"},{"key":"2287_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13287-016-0377-1","volume":"7","author":"J Chen","year":"2016","unstructured":"Chen J, Gu Z, Wu M, Yang Y, Zhang J, Ou J, et al. C-reactive protein can upregulate VEGF expression to promote ADSC-induced angiogenesis by activating HIF-1alpha via CD64\/PI3k\/Akt and MAPK\/ERK signaling pathways. Stem Cell Res Ther. 2016;7:114. https:\/\/doi.org\/10.1186\/s13287-016-0377-1.","journal-title":"Stem Cell Res Ther"},{"key":"2287_CR34","doi-asserted-by":"publisher","first-page":"e70700","DOI":"10.7759\/cureus.70700","volume":"16","author":"M Basheeruddin","year":"2024","unstructured":"Basheeruddin M, Qausain S. Hypoxia-Inducible Factor 1-Alpha (HIF-1alpha) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting. Cureus. 2024;16:e70700. https:\/\/doi.org\/10.7759\/cureus.70700.","journal-title":"Cureus"},{"key":"2287_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"2287_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/pme-2016-0014","volume":"13","author":"JA Abraham","year":"2016","unstructured":"Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med. 2016;13:347\u201360. https:\/\/doi.org\/10.2217\/pme-2016-0014.","journal-title":"Per Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02287-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02287-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02287-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:26:50Z","timestamp":1791826010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02287-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":36,"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02287-w","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to amend to correct the incorrect affiliation of 'Tevfik G\u00fczelbey' and '\u00c7a\u011fr\u0131 Erdim'.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study was conducted at Basaksehir Cam and Sakura City Hospital and was approved by the Clinical Research Ethics Committee (Approval No.: E-96317027-514.10-241604586). Owing to the retrospective design and use of de-identified data, the requirement for informed consent was waived by the committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}